Movement Alert|Axsome Therapeutics Intraday Rise 5.37%, market continues to re-rate Q3 beat and 2027 earnings path

Market Focus11-10

On November 10, Axsome Therapeutics rose 5.37% in Regular Trading, trading at $141.385 per share, with turnover of $29.0073 million.

The move aligns with continued market digestion of the company’s stronger-than-expected third-quarter results and the view that rising Auvelity revenue could support profitability in 2027.

Axsome Therapeutics reported third-quarter EPS of negative $0.25, better than consensus expectations of roughly negative $0.56 to negative $0.63, while revenue rose to $259.7 million from $171.0 million a year earlier and exceeded expectations near $249 million. Auvelity net product sales reached $207.6 million. Subsequent analyst commentary said the company could achieve earnings in 2027, supported by narrowing losses and expanding Auvelity sales, although the ramp in Alzheimer’s disease agitation remains a point to watch. Recent target-price cuts by some firms suggest valuation debate remains active even as ratings stayed constructive.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment